Lexicon stock tumbles after FDA AdCom votes against Zynquista again
The committee was not convinced that the benefit of Zynquista outweighed the risk in adults with type 1 diabetes and chronic kidney disease.
The committee was not convinced that the benefit of Zynquista outweighed the risk in adults with type 1 diabetes and chronic kidney disease.
What's Your Reaction?
